PharmaFocus Today – media

Develop and issue a catalog of innovative drugs for commercial health insurance; Huahai Pharmaceutical receives FDA warning letter

Central Office and State Office: Improve the adjustment mechanism of the basic medical insurance drug catalog, formulate and introduce the innovative drug catalog for commercial health insurance On June 9th, the General Office of the Communist Party of China and the General Office of the State Council issued the “Opinions on Further Ensuring and Improving People’s Livelihood and Focusing on Solving the Urgent Difficulties and Worries of the Masses”. Promote the sharing of high-quality medical and health resources. Promote the expansion and sinking of high-quality medical resources and balanced regional layout, optimize the construction mode, management system, and operation mechanism of regional medical centers. Implement the medical and health infrastructure project, promote the sinking of urban medical resources to county-level hospitals and urban and rural grassroots, and gradually achieve full coverage of the construction of a close county-level medical community. Support high-level hospital personnel, services, technology, management, etc. to ...
- Source: drugdu
- 30
- June 11, 2025
Multiple public funds have adjusted their valuation methods for suspended stocks; Over a hundred ETFs facing liquidity crisis? 丨 Tianci Liangji Early Ginseng

NO.1 Vanguard Fund’s newly appointed Inspector General, Wang Zhongkun Recently, Vanguard Fund announced that the former Inspector General Huang Jinsong has retired and resigned, and Wang Zhongkun has been appointed as the new Inspector General. According to his resume, Wang Zhongkun has served as a member of the Regulatory Department and Secretary of the Secretariat of China Construction Bank Co., Ltd., Secretary of the President’s Office of China Cinda Asset Management Co., Ltd., Secretary of the Board of Directors of Hongyuan Securities Co., Ltd., Marketing Director, Deputy General Manager, and General Manager of the Marketing Department of Cinda Australia Bank Fund Management Co., Ltd., Vice Chairman and Chairman of the Strategic Planning Committee of Leading Biological Agriculture Co., Ltd., Investment Manager of Fengtu Beikong (Ningbo) Investment Management Co., Ltd., and Deputy General Manager of Tianyi Xingchen (Beijing) Technology Co., Ltd. No.2: Yuan Qingwei, the newly appointed General Manager of ...
- Source: drugdu
- 29
- June 11, 2025
Lindsay Huse on Health in Douglas County, Nebraska

The tumult of President Donald Trump’s second term has trickled down from federal agency headquarters in Washington, D.C., to state and local health departments, kicking off a new era fraught with uncertainty even as some of these leaders on the front lines of public health are still struggling to recover from the upheaval caused by the COVID-19 pandemic. What began as a gutting of the federal health workforce has expanded into what some fear could be the upending of the nation’s public health infrastructure. Thus far, the Trump administration has moved to cut approximately $12 billion in funding that had been allocated to state and local health departments, though a federal judge has temporarily blocked cuts for multiple states. As part of our series, Public Health Under Pressure, U.S. News is speaking with stakeholders and officials at local and state health departments around the country to get a better understanding ...
- Source: drugdu
- 24
- June 11, 2025
Salmonella Outbreak Triggers Egg Recall in 9 States

MONDAY, June 9, 2025 (HealthDay News) — A salmonella outbreak tied to a major egg recall has sickened nearly 80 people and sent at least 21 to the hospital, health officials have said. The outbreak has been linked to brown organic and brown cage-free eggs distributed by the August Egg Company, according to a June 6 notice from the U.S. Food and Drug Administration (FDA). More than 1.7 million eggs are being recalled. The Hilmar, Calif.—based company distributed the eggs between February and May. They were sold in nine states: Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington and Wyoming, the Associated Press reported. The U.S. Centers for Disease Control and Prevention (CDC) said 79 people across seven states have gotten sick from the same strain of salmonella linked to the recalled eggs. Salmonella can cause diarrhea, fever, vomiting, stomach cramps and dehydration. Most people recover within a week, ...
- Source: drugdu
- 23
- June 11, 2025
Yipinhong subsidiary’s Dexmedetomidine Hydrochloride Injection obtains registration certificate

June 9, Poinsettia(300723) issued an announcement that the company’s wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. recently obtained the “Drug Registration Certificate” for Dexmedetomidine Hydrochloride Injection approved and issued by the State Food and Drug Administration. This drug is a Class 3 chemical drug and is mainly used for sedation during endotracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia, as well as sedation in intensive care patients. Continuous infusion should not exceed 24 hours. In the first quarter of 2025, Yipinhong achieved revenue of 377 million yuan and net profit attributable to shareholders of the parent company of 56.59 million yuan. https://finance.eastmoney.com/a/202506093425539592.html
- Source: drugdu
- 24
- June 11, 2025
Jianyou Holdings’ subsidiary obtains FDA approval for relocation of daunorubicin hydrochloride injection production site

On June 9, Jianyou shares(603707) announced that its subsidiary Meitheal Pharmaceuticals, Inc. recently obtained the approval letter for the transfer of the production site of daunorubicin hydrochloride injection (20mg/4mL, ANDA No.: 065035) issued by the U.S. FDA, approving the production at Jianjin Pharmaceutical Co., Ltd. The drug is suitable for the treatment of adult acute non-lymphocytic leukemia and can be used in combination with other anticancer drugs. The announcement mentioned that the company has invested about 830,000 yuan in research and development costs in the project of relocating the production site of daunorubicin hydrochloride injection. The newly approved product will be marketed in the United States and is expected to have a positive impact on the company’s operating performance. In the first quarter of 2025, Jianyou Shares achieved revenue of 885 million yuan and net profit attributable to shareholders of the parent company of 84.71 million yuan. https://finance.eastmoney.com/a/202506093425522822.html
- Source: drugdu
- 22
- June 11, 2025
Erkang Pharmaceutical’s Vitamin B6 Injection Passed Consistency Evaluation

On June 9, Erkang Pharmaceutical(300267) released an announcement, vitaminThe B6 injection 1ml:100mg specification has passed the generic drug quality and efficacy consistency evaluation. The company recently received the “Notice of Approval of Supplementary Drug Application” approved by the State Drug Administration, with the approval number of National Medicine Standard H20258096. The drug is mainly used for the prevention and treatment of vitamin B6 deficiency and is included in the “National Basic Medical Insurance”, Work-related Injury Insurance and Maternity Insurance Drug List (2024)”, which is a Class A medical insurance drug. In the first quarter of 2025, Erkang Pharmaceutical achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 28.11 million yuan. https://finance.eastmoney.com/a/202506093425512121.html
- Source: drugdu
- 23
- June 11, 2025
Huaren Pharmaceutical’s wholly-owned subsidiary obtains registration certificate for phenylephrine hydrochloride injection

On June 9, Huaren Pharmaceutical announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical has obtained the Drug Registration Certificate for Phenylephrine Hydrochloride Injection approved and issued by the State Drug Administration. The drug is a prescription drug with a specification of 5ml: 0.5mg. It is registered as a Class 3 chemical drug. The drug approval number is National Medicine Standard H20254431, which is valid until June 2, 2030. Phenylephrine hydrochloride injection is mainly used to treat clinical hypotension caused by vasodilation during anesthesia and is listed as a Class B product of the national medical insurance. According to statistics from Yaozhi.com, the sales of this drug in domestic hospitals in 2024 will be 119 million yuan. In the first quarter of 2025, Huaren Pharmaceutical achieved revenue of 303 million yuan and net profit attributable to shareholders of the parent company of 16.03 million yuan. https://finance.eastmoney.com/a/202506093425445718.html
- Source: drugdu
- 22
- June 11, 2025
Drugdu.com to Exhibit at CPhI China 2025, Marking Nine Years of Advancing Global Connectivity in the Pharmaceutical Sector

The 22nd edition of CPhI China will be held from June 24 to 26, 2025, at the Shanghai New International Expo Centre. Drugdu.com, a global B2B platform specializing in pharmaceutical and medical product trade, will exhibit at Booth W4E80, presenting its latest capabilities in driving digital connectivity across the international healthcare market. Nine Years of Global Trade Enablement and Digital Efficiency Since its founding in 2016, Drugdu.com has evolved into a trusted digital infrastructure serving the global pharmaceutical supply chain. The platform currently connects verified buyers and suppliers across 220+ countries and regions, covering key sectors such as active pharmaceutical ingredients (APIs), finished dosage forms, intermediates, medical devices, diagnostics (IVD), and health products etc. With its data-driven approach, Drugdu.com enhances the efficiency of global sourcing and distribution by enabling precise lead distribution, behavioral analytics, and region-specific market insights. Rather than replicating traditional marketplace models, it focuses on helping users make ...
- Source: drugdu
- 29
- June 11, 2025
Pegcetacoplan Maintains Kidney Benefits at 52 Weeks

Pegcetacoplan, a targeted C3/C3b inhibitor, shows sustained, robust effects on key markers of kidney disease in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to 52-week results from the VALIANT trial. The 26-week results, which were presented last October at Kidney Week 2024, showed a highly significant difference in change in proteinuria from baseline, as measured by the urine protein-to-creatinine ratio (uPCR); the reduction was 67.2% with pegcetacoplan vs 2.9% with placebo (P < .0001). The current findings showed that not only were these benefits sustained in patients who remained on pegcetacoplan, patients who switched from placebo to pegcetacoplan also experienced reductions of similar magnitude, said Fadi Fakhouri, MD, of Lausanne University Hospital and the University of Lausanne, Switzerland. Fakhouri presented the 1-year results at the 62nd European Renal Association (ERA) Congress 2025. VALIANT Open-Label Period The phase 3 VALIANT trial involved 124 patients with ...
- Source: drugdu
- 38
- June 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.